Beta-thalassemia is a group of inherited blood disorders in which production of the beta-globin chains of hemoglobin is reduced or absent. Hemoglobin carries oxygen within red blood cells. Insufficient beta-globin leaves an excess of unpaired alpha-globin chains, damaging developing red cells and causing anemia. The clinical spectrum extends from an asymptomatic carrier state to severe disease requiring regular blood transfusions from early childhood.
Beta-thalassemia is one of the principal forms of thalassemia, distinguished from alpha-thalassemia by the globin chain affected. It is particularly frequent in populations with historical origins around the Mediterranean, the Middle East, South Asia, and Southeast Asia, but migration has made it a worldwide condition. Its importance reflects both its inherited frequency and the lifelong consequences of severe disease: ineffective blood formation, iron accumulation, organ injury, and substantial treatment demands.
The disorder illustrates how a defect in a single gene can produce widely differing clinical outcomes. Residual beta-globin production, fetal hemoglobin levels, other inherited modifiers, and access to treatment all influence severity. Regular transfusion and iron removal have transformed survival, while stem-cell transplantation and genetic therapies can establish sustained production of functional hemoglobin in selected patients.
Genetic basis and inheritance
Beta-thalassemia usually results from pathogenic variants in the HBB gene, located on chromosome 11. This gene encodes beta-globin, a component of adult hemoglobin A, whose molecular composition is . Most disease-causing variants are single-nucleotide changes or small insertions and deletions rather than large chromosomal deletions. They can impair transcription, RNA processing, translation, or the stability of the resulting globin chain. Variants affecting RNA splice sites are particularly important because they can prevent correct assembly of the messenger RNA used to produce beta-globin.
Alleles are commonly classified by their effect on beta-globin synthesis. A allele produces no functional beta-globin, whereas a allele permits some production. Very mild alleles are sometimes designated . These categories describe molecular output, not a complete clinical prognosis: two people with apparently similar HBB genotypes may have substantially different disease because of modifying genes and environmental or treatment-related factors. Some promoter variants produce so little disturbance that carriers have nearly normal blood indices.
The usual inheritance pattern is autosomal recessive inheritance. A person with one typical disease-causing allele and one normally functioning allele generally has beta-thalassemia trait. When both parents carry a pathogenic HBB variant, each pregnancy has a 25% probability of a child inheriting both variants, a 50% probability of a carrier child, and a 25% probability of a child inheriting neither. These probabilities apply independently to each pregnancy; the severity associated with inheriting both variants depends on their particular combination and other modifiers.
Not every affected person is homozygous for the same variant. Compound heterozygosity—inheritance of two different pathogenic alleles—is common. Beta-thalassemia can also occur in combination with structural hemoglobin variants. Hemoglobin E/beta-thalassemia is especially important in Southeast Asia: the hemoglobin E variant both alters the beta-globin protein and activates an abnormal RNA splice site, reducing its production. Its phenotype ranges from mild anemia to transfusion dependence. Inheritance of a beta-thalassemia allele with a sickle hemoglobin allele causes sickle beta-thalassemia, classified within sickle cell disease.
Rare dominantly inherited forms arise from extremely unstable beta-globin chains that damage red-cell precursors even when a normal allele is present. These differ from the usual recessive carrier state and help explain why the simple distinction between “carrier” and “affected” does not capture every molecular form.
Globin imbalance and ineffective blood formation
The central abnormality is an imbalance between alpha- and non-alpha-globin synthesis. In normal adult red cells, alpha- and beta-globin chains are produced in closely coordinated amounts and assembled with heme. In beta-thalassemia, surplus alpha chains cannot form stable, functional hemoglobin on their own. They precipitate within developing red cells, promote oxidative injury, and damage cell membranes. Many affected precursors die in the bone marrow before entering the circulation, a process termed ineffective erythropoiesis.
Red cells that do reach the bloodstream are often small, poorly hemoglobinized, and structurally abnormal. Their shortened survival produces hemolysis, particularly through removal by the spleen. Anemia therefore results from both inadequate effective production and excessive destruction, rather than simply from an insufficient number of marrow precursors. Indeed, the marrow may be highly active and expanded while failing to supply enough durable circulating red cells.
Reduced tissue oxygen delivery stimulates the kidneys to release erythropoietin, which increases erythroid production. This compensatory response can markedly enlarge the marrow space. In inadequately treated severe disease, expansion alters the facial and skull bones, thins cortical bone, and contributes to skeletal deformity. Blood-forming tissue may also develop outside the marrow, especially in the liver, spleen, and paravertebral regions. Such extramedullary hematopoietic masses occasionally compress nearby structures, including the spinal cord.
The expanded erythroid compartment also changes systemic iron regulation. Erythroid precursors release erythroferrone, which suppresses hepatic production of hepcidin, the principal hormone limiting iron entry into plasma. Low hepcidin permits increased intestinal iron absorption and increased iron release from storage cells. Consequently, clinically significant iron overload can develop even without regular transfusions. This mechanism is particularly important in non-transfusion-dependent disease, where iron accumulation may proceed gradually for years.
The developmental switch between hemoglobins explains the typical timing of severe disease. Before birth, fetal hemoglobin, HbF, consists of two alpha and two gamma chains, , and does not require beta-globin. Gamma-globin production normally declines after birth as beta-globin production rises. Infants with severe beta-thalassemia therefore often appear well initially but develop progressive anemia during the first months of life. Persistently increased HbF can partially compensate by pairing gamma chains with excess alpha chains, linking the basic mechanism directly to genetic modifiers and several treatment strategies.
Clinical spectrum and disease classification
Traditional terminology divides beta-thalassemia into minor, intermedia, and major. Beta-thalassemia minor, also called trait, usually describes heterozygous carriers with microcytosis and either no anemia or mild anemia. Beta-thalassemia major describes severe disease presenting in infancy and requiring regular transfusions for survival and normal development. Intermedia denotes clinically significant disease that does not initially require the regular transfusion schedule characteristic of major. These terms remain useful historically but can obscure changes in an individual’s clinical course.
Modern clinical classification commonly distinguishes transfusion-dependent thalassemia, or TDT, from non-transfusion-dependent thalassemia, or NTDT. These categories describe sustained treatment requirements rather than a specific genotype. NTDT does not mean that transfusions are never used: they may be required during infection, surgery, pregnancy, or periods of worsening anemia. Some patients become regularly transfused later in life because of progressive complications, declining exercise tolerance, or other manifestations of inadequate tissue oxygen delivery.
Untreated severe beta-thalassemia commonly presents between approximately 6 and 24 months of age with pallor, poor growth, feeding difficulties, irritability, and abdominal enlargement from hepatosplenomegaly. Progressive marrow expansion can produce characteristic skeletal changes. With effective transfusion, many of these manifestations are prevented or substantially reduced, and the dominant long-term clinical problems shift toward iron burden, treatment complications, and endocrine or cardiovascular disease.
NTDT often becomes apparent later in childhood or adulthood. Manifestations can include persistent anemia, jaundice, splenic enlargement, pigment gallstones, delayed growth, reduced exercise capacity, and extramedullary hematopoiesis. Some complications become more prominent with age, notably thrombosis, pulmonary hypertension, leg ulcers, and iron-related liver injury. A person with relatively few childhood symptoms can therefore develop a significant adult disease burden.
Several inherited modifiers affect severity. Coinherited alpha-thalassemia can reduce excess alpha-chain production and improve chain balance, whereas additional alpha-globin gene copies can worsen it. Variants that sustain fetal hemoglobin production, including those involving the BCL11A and HBS1L–MYB regions, may lessen anemia and transfusion requirements. These effects are not fully captured by the or label.
Clinical classification consequently depends on longitudinal observation, not a single hemoglobin measurement. Growth, skeletal changes, splenic size, symptoms, transfusion history, and organ complications help define the phenotype. Hemoglobin concentration alone is an incomplete measure because physiological adaptation and the degree of ineffective erythropoiesis vary among patients.
Distribution and historical development
Beta-thalassemia has a geographically uneven distribution. Historically high carrier frequencies occur in parts of the Mediterranean basin, North Africa, the Middle East, the Indian subcontinent, and Southeast Asia. Frequencies can differ considerably between neighboring communities because of founder effects, migration patterns, endogamy, and population history. In some high-frequency populations, carrier prevalence reaches several percent or more. A single worldwide percentage conceals this local variation and differences in how carrier status is measured.
The overlap between thalassemia distribution and historical malaria transmission is biologically important. Carrier states can confer a selective advantage against severe malaria in some settings, helping maintain disease-associated alleles despite the reproductive cost of severe biallelic disease. This relationship does not mean that all beta-thalassemia variants have identical protective effects, or that carriers are immune to malaria. It is an example of how infectious pressure can shape the frequency of inherited red-cell traits.
Hemoglobin E/beta-thalassemia contributes substantially to the disease burden in countries including Thailand, Cambodia, and Bangladesh. Mediterranean populations have different common HBB variants, while South Asian and Middle Eastern populations show considerable molecular diversity. Because particular variants may be frequent locally, targeted molecular panels can be useful, although migration and mixed ancestry limit the completeness of panels restricted to a small set of mutations.
International migration has made beta-thalassemia relevant throughout Europe, North America, Australia, and other regions outside its historically recognized distribution. Ancestry can inform epidemiological assessment, but it does not establish or exclude a diagnosis. Population-level burden is also difficult to estimate precisely where newborn screening, laboratory diagnosis, and disease registries are incomplete. Recorded case numbers reflect both biological frequency and the capacity of a health system to identify affected individuals.
The clinical syndrome was described in 1925 by American pediatrician Thomas Benton Cooley and physician Pearl Lee in children with severe anemia, splenic enlargement, and bone changes. “Cooley’s anemia” became a historical name for the severe childhood form. Subsequent work established the inherited nature of thalassemia and distinguished deficient globin synthesis from structural hemoglobin abnormalities.
During the second half of the twentieth century, regular transfusion and iron chelation changed severe beta-thalassemia from a frequently fatal childhood disease into a chronic condition compatible with survival into adulthood. The first successful allogeneic marrow transplantation for thalassemia was reported in 1982. Later molecular studies connected particular HBB variants with impaired gene expression, laying the groundwork for carrier testing, prenatal diagnosis, and genetic treatments.
Laboratory diagnosis and differential diagnosis
Evaluation usually begins with a complete blood count. Beta-thalassemia commonly produces a low mean corpuscular volume and low mean corpuscular hemoglobin. In trait, the red-cell count is often relatively preserved or increased despite the small cell size, whereas hemoglobin may be normal or mildly reduced. A blood film can show microcytosis, hypochromia, target cells, and variable variation in cell shape and size. More severe disease may produce nucleated red cells and marked abnormalities.
Hemoglobin analysis is central to diagnosis. High-performance liquid chromatography and capillary electrophoresis separate and quantify hemoglobin fractions. After infancy, beta-thalassemia trait typically shows increased hemoglobin A₂, often above approximately 3.5%, sometimes with a modest increase in HbF. Laboratory-specific reference ranges and the clinical context matter. Borderline results can occur with mild alleles, coinherited delta-globin abnormalities, iron deficiency, and analytical interference from other hemoglobin variants.
Severe beta-thalassemia generally shows a large HbF fraction. Untreated disease produces no endogenous HbA, while genotypes can produce variable amounts. Recent transfusion complicates interpretation because donor red cells introduce HbA and other donor hemoglobin fractions. In newborns, HbF is normally predominant, and HbA₂ has not yet reached its later childhood level; adult diagnostic thresholds therefore do not apply directly. Newborn screening patterns can indicate severe disease, but confirmatory testing establishes the diagnosis.
Molecular analysis of HBB can identify the underlying variants and clarify uncertain hemoglobin results. DNA sequencing detects many small sequence changes, while deletion or duplication analysis addresses variants not captured by routine sequencing. Testing other globin genes may explain an unexpectedly mild or severe phenotype. Family studies can establish whether identified variants are on opposite parental chromosomes, an important distinction when interpreting recessive disease.
The principal differential diagnosis for microcytosis is iron-deficiency anemia, although the two conditions can coexist. Ferritin and other iron measurements help distinguish them, but ferritin rises with inflammation and liver injury. Mathematical indices derived from the blood count, such as the Mentzer index, can assist screening but do not independently establish a diagnosis.
Other considerations include alpha-thalassemia, anemia associated with chronic inflammation, sideroblastic disorders, and lead toxicity. Alpha-thalassemia trait often has normal adult hemoglobin fractionation, making molecular analysis important in some cases. Bone-marrow biopsy is not ordinarily needed to diagnose straightforward beta-thalassemia. The most secure interpretation combines blood indices, iron status, hemoglobin analysis, molecular findings where indicated, and family history.
Transfusion and control of iron burden
Regular red-cell transfusion treats anemia and suppresses the ineffective erythropoiesis responsible for marrow expansion, skeletal changes, and excessive extramedullary blood formation. In transfusion-dependent disease, commonly used regimens maintain pretransfusion hemoglobin around 9.5–10.5 g/dL, with individual variation for clinical circumstances. Transfusions are often given every two to five weeks. The intended effect is not simply temporary symptom relief but sustained support of growth, activity, and organ function.
Repeated transfusion introduces a predictable iron burden because the body lacks a regulated pathway for excreting large amounts of iron. A typical adult red-cell unit contains roughly 200–250 mg of iron, with the amount varying by product volume. Over time, iron accumulates in the liver, heart, and endocrine organs. Increased intestinal absorption adds to this burden, although transfusional iron usually dominates in regularly transfused patients.
Chelation therapy uses molecules that bind iron and promote its excretion. The principal established agents are deferoxamine, deferiprone, and deferasirox. Deferoxamine is generally administered by prolonged subcutaneous or intravenous infusion, whereas deferiprone and deferasirox are oral medicines. Their distribution, routes of iron excretion, adverse effects, and practical demands differ. Combination regimens are used in selected circumstances, particularly when iron burden is difficult to control or cardiac iron is present.
Monitoring uses complementary measurements rather than a single definitive blood test. Serial ferritin provides a practical indication of trends, but infection, inflammation, and hepatic disease can alter its value independently of stored iron. Magnetic resonance imaging methods estimate liver iron concentration and assess cardiac iron through relaxation measurements such as T2*. In commonly used validated cardiac methods, a myocardial T2* below 20 milliseconds indicates iron loading, while values below 10 milliseconds are associated with substantially increased cardiac risk. Interpretation depends on the imaging protocol and clinical setting.
Transfusion also has non-iron risks, including allergic and febrile reactions, alloimmunization, and transmission of infection. Modern donor screening and testing have reduced infectious risks substantially where comprehensive blood-safety systems operate. Leukoreduction and red-cell antigen matching are components of many thalassemia transfusion programs, with matching beyond ABO and RhD used to limit alloantibody formation.
Chelators require safety monitoring as well as assessment of iron removal. Deferiprone can cause severe neutropenia or agranulocytosis; deferasirox can affect renal and hepatic function; and deferoxamine can cause auditory, ocular, and skeletal toxicity under some exposure conditions. These differences make long-term iron management a balance between preventing iron-mediated injury and avoiding excessive or toxic chelation.
Organ complications and longitudinal care
Iron-related cardiac disease has historically been a major cause of death in transfusion-dependent beta-thalassemia. Myocardial iron can cause arrhythmias and heart failure, sometimes before severe symptoms develop. Cardiac MRI transformed assessment by detecting myocardial iron more directly than serum ferritin or liver iron measurements. Improved surveillance and effective chelation have reduced cardiac mortality in well-resourced treatment settings, although risk remains where iron control or access to monitoring is inadequate.
The liver receives iron from both transfusions and increased absorption. Persistent overload can lead to fibrosis and cirrhosis. Historical exposure to transfusion-transmitted hepatitis C or hepatitis B adds another pathway to liver injury. The contributions of iron, viral infection, and metabolic liver disease can overlap. Liver complications may continue to require assessment even after transfusion independence because previously accumulated iron is not immediately eliminated.
Endocrine injury includes delayed puberty, hypogonadism, impaired growth, hypothyroidism, and disturbances of glucose regulation, including diabetes mellitus. Iron can damage the pituitary gland, pancreas, and other endocrine tissues. Growth impairment is multifactorial: chronic anemia, nutritional deficits, endocrine dysfunction, liver disease, and treatment-related effects may all contribute. Bone disease likewise reflects marrow expansion, hormonal abnormalities, altered bone remodeling, and other factors; osteoporosis and fractures can occur despite otherwise effective hematological treatment.
NTDT has a partially different complication profile. Chronic hemolysis, abnormal red-cell membranes, platelet activation, and endothelial dysfunction contribute to a hypercoagulable state. Thrombosis is particularly associated with splenectomy and other risk factors. Pulmonary hypertension can arise through several mechanisms, including chronic anemia, hemolysis-associated vascular changes, and thromboembolic disease. A raised estimate on echocardiography is not equivalent to a definitive hemodynamic diagnosis.
Splenic enlargement can increase red-cell destruction and transfusion requirements, but splenectomy has become more selective because it increases risks of severe infection and thrombotic complications. Removal of the spleen does not correct the underlying globin defect. Historical practices of routine splenectomy therefore differ from contemporary approaches that weigh its hematological benefits against long-term risks.
Longitudinal care also addresses fertility, pregnancy, dental and skeletal health, infection risk, and psychosocial burden. Pregnancy can be complicated by pre-existing cardiac or endocrine disease, changing transfusion needs, and altered suitability of some medicines. Treatment schedules, repeated procedures, and uncertainty about complications can affect education, employment, and health-related quality of life, even when conventional laboratory indicators are well controlled.
Medicines that modify erythropoiesis
Disease-modifying medicines seek to improve effective red-cell production or reduce the imbalance between globin chains. These approaches differ from transfusion, which supplies mature donor cells, and from chelation, which removes accumulated iron. Their effects are usually measured through hemoglobin concentration, transfusion burden, or both. A reduction in transfusion requirements can be clinically important without amounting to complete transfusion independence.
Luspatercept is a recombinant fusion protein that binds selected ligands in the transforming growth factor-beta superfamily and reduces signaling associated with impaired late-stage erythroid maturation. Its biological action is more specific than a general stimulation of marrow activity: it promotes maturation within an already expanded but inefficient erythroid compartment. It received United States approval in 2019 for anemia in adults with beta-thalassemia requiring regular red-cell transfusions. Approved indications differ between jurisdictions.
In the pivotal BELIEVE randomized controlled trial, the primary endpoint was a reduction in transfusion burden of at least 33%, with a reduction of at least two red-cell units, during weeks 13–24 compared with baseline. This endpoint was reached by 21.4% of luspatercept recipients and 4.5% of placebo recipients. The result demonstrated efficacy for a defined transfusion-reduction outcome, not universal freedom from transfusion. Responses vary, and longer observation can identify benefits not apparent in a single assessment interval.
Reported adverse effects include bone pain, joint pain, dizziness, and hypertension. Thromboembolic events are an important safety consideration, especially in patients with existing risk factors. Extramedullary hematopoietic masses also require attention in the clinical assessment of some patients receiving erythroid maturation treatment. As with other therapies, the clinical value depends on both benefit and the patient’s broader disease characteristics.
Hydroxyurea can increase fetal hemoglobin and has been studied and used in selected beta-thalassemia phenotypes, particularly some forms of NTDT. Its effects are less predictable than in sickle cell disease, and the evidence base and regulatory position vary by setting. A higher HbF level may improve globin-chain balance, but response depends on genetic background and cannot be inferred from the drug’s success in a different hemoglobin disorder.
Other investigational strategies target erythroid metabolism, iron availability, or gene regulation. Pyruvate kinase activation aims to improve red-cell energy metabolism and survival. Approaches involving hepcidin pathways or reduced iron delivery attempt to limit toxic iron excess and potentially improve ineffective erythropoiesis. These mechanisms address interconnected abnormalities, but their success must be established through clinical outcomes rather than biochemical plausibility alone.
Stem-cell transplantation and genetic therapies
Allogeneic hematopoietic stem-cell transplantation can replace the patient’s blood-forming system with donor cells capable of producing adequate beta-globin. It is an established potentially curative treatment, especially when performed before major iron-related organ damage. Outcomes depend on age, donor compatibility, conditioning regimen, pre-existing disease, and center experience. In favorable pediatric matched-sibling settings, overall survival commonly exceeds 90%, although those results do not apply uniformly to all patients or donor types.
Transplantation requires preparative treatment to permit donor-cell engraftment and carries risks including infection, infertility, graft failure, organ toxicity, and graft-versus-host disease. Alternative donors and haploidentical approaches have expanded the potential donor pool, but introduce distinct technical and immunological considerations. Successful transplantation stops the production of thalassemic red cells, yet existing iron overload and established organ injury may persist.
Autologous gene therapy avoids the need for an allogeneic donor. Hematopoietic stem and progenitor cells are collected from the patient, genetically modified outside the body, and returned after conditioning chemotherapy. Because the cells are autologous, classical donor-derived graft-versus-host disease is avoided. However, collection, manufacturing, conditioning, prolonged cytopenias, and long-term follow-up remain substantial components of treatment.
Betibeglogene autotemcel, approved in the United States in 2022 for adult and pediatric patients with beta-thalassemia requiring regular transfusions, uses a lentiviral vector to introduce a modified beta-globin gene. The resulting beta-globin can assemble into functional hemoglobin and reduce the need for donor red cells. Trials demonstrated sustained transfusion independence in a substantial majority of evaluable participants, but not in every treated individual. Integrating-vector therapies require long-term surveillance for potential delayed effects, including abnormal clonal blood-cell expansion.
Exagamglogene autotemcel uses CRISPR–Cas gene editing to disrupt an erythroid-specific regulatory region of BCL11A. BCL11A normally suppresses gamma-globin expression after infancy. Editing its erythroid enhancer increases HbF production, enabling gamma chains to pair with alpha chains and compensate for deficient beta-globin. The approach does not directly repair the patient’s HBB variants. It received United States approval in January 2024 for transfusion-dependent beta-thalassemia in patients aged 12 years and older.
Genetic treatments do not remove all treatment-related risk. Myeloablative conditioning can cause serious acute toxicity and infertility, while genome modification introduces platform-specific questions requiring extended monitoring. Trial endpoints such as transfusion independence over a defined interval demonstrate major hematological benefit but do not, by themselves, establish lifelong freedom from complications. Manufacturing capacity, specialist infrastructure, cost, and eligibility criteria also determine how broadly these therapies can be used.
Carrier identification, reproductive genetics, and access to care
Carrier identification links laboratory medicine with reproductive genetics. Beta-thalassemia trait is usually medically mild, but recognizing it clarifies the cause of persistent microcytosis and identifies the possibility of clinically significant disease in offspring when both reproductive partners carry relevant hemoglobin variants. Screening programs may use blood counts followed by hemoglobin analysis and, when indicated, molecular testing. Testing only for a small number of common variants can miss less frequent or population-specific alleles.
Genetic counseling explains inheritance, the range of possible phenotypes, the limits of prediction, and available reproductive testing pathways. Prenatal diagnosis can examine fetal DNA obtained through chorionic villus sampling or amniocentesis when familial variants are known. Preimplantation genetic testing for monogenic disease can assess embryos created through in vitro fertilization. These methods differ in timing, technical demands, and the information they provide; their availability depends on healthcare systems and national regulation.
Counseling is complicated by the variable severity of some genotypes, especially hemoglobin E/beta-thalassemia and combinations involving mild beta-thalassemia alleles. Molecular diagnosis can establish that a child has inherited particular variants without precisely predicting future transfusion needs or complications. Modifier genes improve understanding of this variability, but they do not yield a fully deterministic forecast for every individual.
Population programs in several Mediterranean settings have combined public education, carrier screening, counseling, and prenatal diagnosis, and have been associated with substantial reductions in births affected by severe thalassemia. Such outcomes depend on sustained laboratory capacity, participation, and reproductive services. Ethical evaluation includes informed consent, confidentiality, nondirective counseling, and avoidance of discrimination against carriers or affected people. Carrier status does not imply illness, reduced personal worth, or a single appropriate reproductive choice.
Access to basic treatment remains highly unequal. Safe blood supplies, continuous chelator availability, reliable iron assessment, and specialist follow-up are not uniformly accessible in regions with high disease frequency. Interruptions in transfusion or chelation can have consequences that accumulate over years. The gap between highly specialized genetic therapies and inconsistent access to established care is therefore a major feature of the global disease burden.
Disease registries and long-term cohort studies help characterize survival, complications, and changing treatment requirements. Important outcomes include organ function, fertility, participation in education and work, and patient-reported treatment burden, rather than hemoglobin values alone. Comparisons across countries require attention to age structure, genotype distribution, transfusion practice, and completeness of follow-up, because these factors strongly influence apparent disease severity and survival.